Israel China Biotechnology (ICB) Ltd Cash Flow-to-Debt Ratio
Israel China Biotechnology (ICB) Ltd cash flow-to-debt ratio. Israel China Biotechnology (ICB) Ltd (ICB) has a Cash Flow-to-Debt Ratio of -0.26x as of June 2021, meaning its operating cash flow of ILA-1.06 Million could theoretically repay 0% of its total liabilities (ILA4.11 Million) in one year. Check cash flow quality index of Israel China Biotechnology (ICB) Ltd to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Israel China Biotechnology (ICB) Ltd (2015–2020)
Cash flow-to-debt ratio of Israel China Biotechnology (ICB) Ltd from 2015 to 2020. Historical debt coverage capacity for Israel China Biotechnology (ICB) Ltd across 6 annual periods. Also explore Israel China Biotechnology (ICB) Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Israel China Biotechnology (ICB) Ltd Cash Flow-to-Debt Ratio by Year (2015–2020)
Israel China Biotechnology (ICB) Ltd cash flow-to-debt ratio by year from 2015 to 2020. Year-by-year debt coverage analysis for Israel China Biotechnology (ICB) Ltd. For the full cash flow conversion analysis, see ICB operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (ILA) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2020 | -0.55x | ILA-4.34 Million | ILA7.87 Million | ▼ -26.3% |
| 2019 | -0.44x | ILA-4.22 Million | ILA9.68 Million | ▲ +77.4% |
| 2018 | -1.93x | ILA-4.75 Million | ILA2.46 Million | ▼ -74.6% |
| 2017 | -1.11x | ILA-3.17 Million | ILA2.87 Million | ▲ +39.7% |
| 2016 | -1.83x | ILA-3.94 Million | ILA2.15 Million | ▼ -15.1% |
| 2015 | -1.59x | ILA-3.81 Million | ILA2.39 Million | — |